ストックスクリーナーアプリを入手
100.75
3.72%
3.61
アフターアワーズ：
100.75
Inhibrx Biosciences Inc (INBX) 最新ニュース
Top Cybin (HELP) Competitors 2026 - MarketBeat
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In? - Sahm
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
INBX News | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences urges continued research to address unmet needs in rare cancer treatment - Traders Union
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
INBX Forecast — Price Target — Prediction for 2027 - TradingView
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart - Sahm
Inhibrx Biosciences (INBX) Gains 2.44%, Approaches Key Resistance at $99.93Order Block - dars.gov.et
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
INBX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline AdvancesEarnings Sentiment Score - dars.gov.et
(INBX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart - Sahm
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences Inc (INBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibrx Biosciences Inc (INBX) Institutional Confidence - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibrx Biosciences Inc (INBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com Australia
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Pa - GuruFocus
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy - TipRanks
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy - Stock Titan
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com - Investing.com Australia
FDA accepts Inhibrx Biosciences filing for ozekibart in metastatic chondrosarcoma - Traders Union
Inhibrx Biosciences stock gains after FDA accepts drug filing - Investing.com
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients With Conventional Chondrosarcoma - Moomoo
Number of shareholders of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
(INBX) Risk Channels and Responsive Allocation - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Stock Gains on Operational UpdatesRetail Earnings Report - newsline.com
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike - Stock Titan
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options - Stock Titan
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22 - Stock Titan
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting - TipRanks
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO - Stock Titan
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Stifel reiterates Inhibrx Biosciences stock rating on durability data By Investing.com - Investing.com Canada
Inhibrx Biosciences targets research advances at ASCO26 to accelerate new cancer treatments - Traders Union
INBX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue R&D FocusEPS Growth Report - newsline.com
INBXInhibrx Biosciences Inc Forecast, Target Price - Finviz
Inhibrx Biosciences (INBX) Slips 2% as Stock Tests Key Support Amid Biotech VolatilityVolatility Breakout Picks - The Legal Advocate
(INBX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):